Scientific Advisory Board
Bridget Bax, PhD+
Senior Researcher at Division of Clinical Developmental Sciences at St. George’s Hospital and visiting Professor at the London Metropolitan University. Expert on metabolic diseases and Enzyme based therapies therapy.
Prof. Arthur E. Frankel, MD+
Head of the Division of Hematology/Oncology at the Scott & White Cancer Institute Texas, United States and Professor at the Texas Health Science Center College of Medicine. Worked on the deprivation of amino acid as a cancer therapy.
Iman El-Hariry, MD, PhD - Chief Medical Officer+
Iman El-Hariry, M.D., Ph.D. has served as our Chief Medical Officer and employee of our wholly-owned U.S. subsidiary, ERYTECH Pharma, Inc., since June 2015. Prior to her appointment as Chief Medical Officer, she served as President of Azure Oncology Consulting from July 2014 to June 2015 and also assisted us in a consulting role from November 2014 to June 2015. Dr. El-Hariry served as Vice President of Clinical Research at Synta Pharmaceuticals from November 2010 to July 2014 and as Global Head of Oncology at Astellas Pharma, Inc. from June 2009 to July 2010. From 2001 to 2009, she served as Director of Clinical Development, Oncology at Glaxo Smith Kline. Dr. El-Hariry is a licensed oncologist with an M.D. from Alexandria Medical School (Egypt) and a Ph.D. in Cancer Research from Imperial College of Science and Medicine (United Kingdom).
Kurt Gunter, MD, PhD, FASCP+
President 2012-2014 of the International Society of Cellular Therapy. Until the end of March 2013, he was Global Head of Regenerative Medicine at Hospira Chicago, US. Kurt has extensive experience in medicine (Hematology & Transfusion Medicine) and medical regulatory affairs. He served at the US FDA where he was appointed Acting Deputy Director within the Center for Biologics Evaluation and Research (CBER).
Philip L. Lorenzi, PhD.+
Supervisor of Laboratory and Research, MD Anderson Cancer Center, Houston, Texas, US. Translational research in pharmacogenomics and biomarker identification and mechanism of action. Expert in asparagine synthetase in cancerous cells.
Prof. Eric Raymond, MD, PhD+
Head of Medical Oncology Department, CHUV in Lausanne, Switzerland. Expert in innovative therapies for solid tumours.